No profile data available.
Inhibrx Biosciences, Inc. (INBX) is a healthcare company in the additional cancer treatment drugs industry, based in La Jolla, United States, with about 109 full-time employees.
It reported revenue of $1.30 million for fiscal year 2025, up 550.0% from fiscal year 2024, and net income of -$140.06 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0, down 100.0% from a year before. Its market capitalization was $1.40 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.
Inhibrx Biosciences reported $1.30 million in revenue for fiscal year 2025, up 550.0% from $200,000 in fiscal year 2024. In Q2 2026 revenue was $0.
$1.40 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Zymeworks Inc. (ZYME), UroGen Pharma Ltd. (URGN), Nuvation Bio Inc. (NUVB), AnaptysBio, Inc. (ANAB).